Industry & Policy News

[Goethe University Frankfurt (EurekAlert!)] Biochemist and structural biologist Robert Tampé, a specialist in the structural analysis of membrane protein complexes of the adaptive immune system, has now been awarded a five-year, €2.5 million European Research Council Advanced Grant for his project Unraveling the Supramolecular Architecture of Molecular Machineries in Adaptive Immunity

[Harvard Medical Soon] Sooner than you may think, says Dr. Catherie Wu, Harvard Medical School professor of medicine and, was honored in February with the $1 million Sjöberg Prize, given for cancer research.

[Palisade Bio, Inc.] Palisade Bio, Inc. announced the completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 inhibitor prodrug in development for patients affected by ulcerative colitis (UC). PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.

[Case Western Reserve University] With a new five-year, $1.84 million grant from the National Cancer Institute, researchers from Case Western Reserve University hope to take a step closer to developing new treatment options for people with metastatic colorectal cancer by studying how a protein involved in colorectal cancer growth functions.

[AviadoBio] AviadoBio announced that the first patient has been treated in the Phase I/II ASPIRE-FTD trial evaluating AviadoBio’s investigational gene therapy, AVB-101, in people with frontotemporal dementia with progranulin gene mutations.

[Diamyd Medical] Diamyd Medical’s precision medicine Phase III trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events have been reported, and no patients have discontinued the trial.